AstraZeneca To Continue Collaboration With Shionogi On Crestor
This article was originally published in PharmAsia News
AstraZeneca CEO David Brennan stated Oct. 8 that the company will keep the same relationship with Japanese pharmaceutical company Shionogi, after Shionogi's purchase of American firm Sciele Pharma. Currently, AstraZeneca and Shionogi are collaborating in marketing hyperlipidemia drug Crestor (rosuvustatin). Brennan also disclosed that the company will keep the current staff level of 3,200 in Japan, amid its effort to cut work force and streamline operations in the U.S. and Europe. Shionogi launched the take over bid for Sciele in September and completed the bid Oct. 6 in an effort to strengthen the company's sales network in the U.S. market. (Click here for more - Japanese language) "AstraZeneca To Continue The Same Relationship With Shionogi - AstraZeneca CEO" - Nikkei Sangyo News (10/8/08)
You may also be interested in...
Indianapolis-based Eli Lilly has been able to maintain a partnership with Osaka-headquartered Shionogi for exactly one century. Their relationship started when Shionogi started importing gelatin capsules from Lilly back in 1909. Alliance managers from Lilly and Shionogi sat down with PharmAsia News' Tokyo bureau to talk about what has made the partnership so successful.
A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.